GT Biopharma, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
3.33
|
|
Average Rating
|
3.50
|
|
# Strong Buys
|
0
|
|
# Buys
|
1
|
|
# Holds
|
1
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.11
|
-0.22
|
-0.11
|
-100.00%
|
|
2022-06-30
|
-0.17
|
-0.10
|
0.07
|
41.18%
|
|
2022-03-31
|
-0.31
|
-0.17
|
0.14
|
45.16%
|
|
2021-12-31
|
-0.21
|
-0.52
|
-0.31
|
-147.62%
|
|
2021-09-30
|
-0.21
|
-0.17
|
0.04
|
19.05%
|
|
2021-06-30
|
-0.28
|
-0.15
|
0.13
|
46.43%
|
|
2021-03-31
|
-0.04
|
-3.39
|
-3.35
|
-8375.00%
|
|
2020-12-31
|
-0.04
|
-3.39
|
-3.35
|
-8375.00%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-0.49
|
|
2021-12-31
|
-4.23
|
|
2020-12-31
|
-3.57
|
|
2019-12-31
|
-0.67
|
|
2018-12-31
|
-5.16
|
|
2017-12-31
|
-234.22
|
|
2016-12-31
|
-499.27
|
|
2015-12-31
|
-19358.43
|
|
2014-12-31
|
-50683.04
|
|
2013-12-31
|
-1346.82
|
|
2012-12-31
|
-2911.20
|
|
2011-12-31
|
-8229.30
|
|
2010-12-31
|
-44184.79
|
|
2009-12-31
|
-62987.57
|
|
2008-12-31
|
-132369.12
|
|
2007-12-31
|
-39210.94
|
|
2005-12-31
|
-85310.14
|
|
2004-12-31
|
-2791765.62
|